Valuation: CSL Limited

Market Cap 41.15B 35.96B 33.24B 30.71B 57.84B 3,953B 58.89B 396B 156B 1,936B 155B 151B 6,664B P/E 2026 *
-46.2x
P/E 2027 * 28.6x
Enterprise Value 50B 43.7B 40.39B 37.32B 70.28B 4,803B 71.55B 482B 189B 2,352B 188B 184B 8,098B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 3.15x
Free-Float
99.3%
Yield 2026 *
3.32%
Yield 2027 * 3.4%
1 day-0.98%
1 week-2.05%
Current month+6.11%
1 month+15.37%
3 months-12.69%
6 months-30.54%
Current year-29.48%
1 week 120.1
Extreme 120.1
126.98
1 month 104.74
Extreme 104.74
126.98
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap.
06-01Buy

Director

1,036 0.0002%
05-26Buy

Chief Executive Officer

1,100 0.0002%
05-26Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%-2.05%-51.43%-52.96% 41.15B
-1.05%-2.97%+14.99%-8.68% 66.75B
-1.32%-8.39%+34.74%+193.12% 50.65B
-2.29%+36.80%+36.80%+36.80% 42.55B
-8.17%-6.68%+44.20%-31.18% 28.34B
+0.64%-15.46%+105.17%-44.43% 26.76B
+0.57%-2.69%+64.16%+86.01% 22.95B
+7.83%+12.47%+12.86%+207.78% 20B
-1.56%-5.38%+53.69%+123.21% 16.3B
+1.22%+7.93%+76.33%+361.53% 16.48B
Average -0.53%-3.53%+39.15%+87.12% 33.19B
Weighted average by Cap. -0.99%-3.96%+30.55%+62.10%

Financials

2026 *2027 *
Net sales 15.39B 13.45B 12.43B 11.49B 21.63B 1,478B 22.03B 148B 58.18B 724B 57.81B 56.54B 2,493B 15.64B 13.66B 12.63B 11.67B 21.98B 1,502B 22.37B 151B 59.1B 735B 58.73B 57.43B 2,532B
Net income -894M -781M -722M -667M -1.26B -85.83B -1.28B -8.61B -3.38B -42.03B -3.36B -3.28B -145B 1.18B 1.03B 956M 883M 1.66B 114B 1.69B 11.4B 4.47B 55.65B 4.44B 4.35B 192B
Net Debt 8.85B 7.73B 7.15B 6.6B 12.44B 850B 12.66B 85.26B 33.45B 416B 33.24B 32.51B 1,433B 8.07B 7.05B 6.52B 6.02B 11.34B 775B 11.55B 77.75B 30.5B 380B 30.31B 29.64B 1,307B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
15/07/26 A$121.75 -0.98% 901,452
14/07/26 A$122.96 +1.34% 697,252
13/07/26 A$121.34 -1.26% 1,504,392
10/07/26 A$122.89 -2.10% 1,052,178
09/07/26 A$125.53 +0.99% 943,037
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
85.93USD
Average target price
96.64USD
Spread / Average Target
+12.46%

Quarterly revenue - Rate of surprise